secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2026-07-16T11:00:46+00:00
Accession:  0001140361-26-028602
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed reports positive 12-month OLE data for TPIP in PAH; sustained improvement across endpoints
--------------------------------------------------------------------------------

- 6MWD improved +55.7m (TPIP continued) and +54.1m (placebo crossed) from baseline at Month 12.
- NT-proBNP reduced ~60% in both groups; WHO Functional Class I/II achieved in ~80% of patients.
- REVEAL Lite 2.0 score improved 2.0 points (TPIP continued) and 1.4 points (placebo crossed); ~65% low-risk.
- TPIP well-tolerated with no new safety signals; most common TEAEs: headache (28.6%), cough (15.4%).
- Phase 3 PALM-PAH trial initiated; topline Phase 2b results previously reported June 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036126028602/0001140361-26-028602-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036126028602/ef20078093_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-028602

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer